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Abstract
Background—Insurance may lengthen or inhibit time to follow-up after positive screening 
mammography. We assessed the association between insurance status and time to initial diagnostic 
follow-up after a positive screening mammogram.
Methods—Using 1995-2010 data from a North Carolina population-based registry of breast 
imaging and cancer outcomes, we identified women with a positive screening mammogram. We 
compared receipt of follow-up within 60 days of screening using logistic regression and evaluated 
time to follow-up initiation using Cox proportional hazards regression.
Results—Among 43,026 women included in the study, 73% were <65 years and 27% were 65+. 
Median time until initial diagnostic follow-up was similar by age group and insurance status. In 
the adjusted model for women <65, uninsured women experienced a longer time to initiation of 
diagnostic follow-up (hazard ratio (HR) =0.47 (95% confidence interval (95% CI)) =0.25-0.89) 
versus women with private insurance. There was an increased odds of these uninsured women not 
meeting the CDC guideline for follow-up within 60 days (1.59, 95% CI (1.31-1.94). Among 
women ages 65+, women with private insurance experienced a faster time to follow-up (adjusted 
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HR=2.09, 95% CI=1.27-3.44) compared to women with Medicare and private insurance. 
Approximately 10% of women had no follow-up by 365 days.
Conclusions—We found differences in time to initial diagnostic follow-up after a positive 
screening mammogram by insurance status and age group. Uninsured women under age 65 years 
at a positive screening event had delayed follow-up.
Impact—Replication of these findings and examination of their clinical significance warrant 
additional investigation.
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Introduction
Screening mammography has been associated with as much as a 20% reduction in breast 
cancer mortality among women ages 40-74 years (1, 2) and mammography remains the 
preferred method for breast cancer screening in the U.S. (1). An estimated 54-60% of breast 
cancers are detected via screening mammography (3-5) highlighting its importance in breast 
cancer detection. Approximately 10% of screening mammograms require additional follow-
up imaging and about 2% require a biopsy (6, 7). A dimension of screening that may impact 
breast cancer mortality is the receipt of appropriate and timely follow-up after a positive 
screening mammogram, especially if the follow-up delays necessary treatment. Breast 
cancer screening via mammography is only effective in reducing mortality if followed by 
timely diagnosis and treatment.
Currently, the only U.S. guideline regarding the length of time in which follow-up should 
occur after a positive screening mammogram comes from the Centers for Disease Control 
and Prevention (CDC). The CDC guidelines recommend women with a positive screening 
mammogram complete diagnostic work-up of a positive screening mammogram within 60 
days of the initial positive screen (8, 9). Delayed (>60 days, based on the CDC guideline, as 
defined in the literature) follow-up after a positive screening mammogram may contribute to 
disparities in breast cancer outcomes and subsequently mortality since follow-up times of 
3-6 months have been associated with larger tumor size at diagnosis and reduced survival 
(10-14).
Many factors may contribute to prolonged initiation of diagnostic follow-up after a positive 
screening mammogram result (15). Healthcare system factors known to influence receipt of 
appropriate diagnostic follow-up include adequate communication with health care 
professionals, physician referral, and facility type (16, 17). Prior studies have investigated 
patient factors such as race, education, and rural/urban residence that influence diagnostic 
follow-up time (18). However, few studies have examined the influence of insurance on 
diagnostic follow-up time. Insurance status refers to whether someone is uninsured or 
insured and among those with insurance designates the specific insurance provider.
Although the impact of insurance status as a determinant of breast cancer care (access to 
screening, stage at diagnosis, receipt of treatment) has been well-documented (19-24), the 
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effect of insurance status on time to diagnostic follow-up initiation after a positive screening 
mammogram is not well understood. Associations may vary by insurance status and prior 
studies often include members of a single insurance status or combine multiple insurance 
groups. The primary objective of this study is to assess the association between insurance 
status and the time to initiation of diagnostic follow-up after a positive screening 
mammogram in a large, racially diverse population-based breast cancer screening 
population.
Materials and Methods
Data and Study Population
We use data from the Carolina Mammography Registry (CMR), a National Institutes of 
Health (NIH) funded, population-based breast imaging registry in North Carolina. CMR is 
an active member of the Breast Cancer Surveillance Consortium (BCSC) (25) and collects 
data from women undergoing breast imaging at community radiology facilities, from 
radiologists performing the imaging examinations, and from pathology data collected by the 
breast imaging facilities. The CMR data include patient demographics, patient risk factors 
(such as breast density and family history of breast cancer), the type of imaging performed, 
the reason for the examination, and the radiologists’ assessment and recommendation for 
follow-up. These data are linked with cancer outcomes from the North Carolina Central 
Cancer Registry (NC-CCR) and abstracted hospital pathology reports as well as with vital 
status data from the State Center for Health Statistics.
This study includes data collected between 1995-2010 from women ages 40 and older 
undergoing screening mammography with non-missing insurance status and no personal 
history of breast cancer. At the time of the mammogram, the radiologist recorded whether 
the examination was a screening or diagnostic mammogram. A screening mammogram was 
defined using BCSC definitions (4, 26) and includes routine views of the breast among 
women without breast symptoms such as pain or lump. To be considered positive, the 
screening mammogram had to be assigned a Breast Imaging Reporting and Data System 
(BI-RADS) assessment of 0 (needs additional imaging), 4 (suspicious abnormality), 5 
(highly suggestive of malignancy), or 3 (probably benign finding) coupled with the 
radiologist's recommendation for immediate follow-up (surgical consult, biopsy, or fine 
needle aspiration) (26, 27). Among women with more than one positive screening 
mammogram in CMR, one positive screening exam was randomly selected. Women 65 years 
and older reporting no insurance were excluded from analyses due to small numbers (n=24, 
less than 1% of the 65+ sample).
Exposure and Outcome Assessment
Insurance paying for the exam are self-reported by the woman at the time of the screening 
mammogram and comprises the following categories: no insurance, Medicaid only, 
Medicare only, Medicare & Medicaid (usually referred to as “dual coverage”), Medicare & 
private, and private only. Initial diagnostic follow-up was defined as the first of subsequent 
breast imaging (such as diagnostic mammography, breast ultrasound, MRI) or breast biopsy 
following the positive screening mammogram. For each positive screening mammogram, we 
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looked forward one year for subsequent imaging or biopsy and then ascertained the time 
until initial diagnostic follow-up as the number of days from the positive screening 
mammogram until the date of the first follow-up event, censoring at 365 days. A woman 
could have a follow-up time of zero days if the positive screening mammogram and the first 
diagnostic follow-up event were performed on the same day.
Covariates
Covariates of interest included demographic information as reported by the woman at the 
time of the mammogram using a standard patient questionnaire. These variables included: 
age (age at time of positive screening mammogram); race (Black, White, Asian, Hispanic, 
American Indian, Other); and education (less than high school diploma, high school 
graduate or equivalent, some college, college graduate).
An indicator of urban/rural patient residence was based on the zip code of the patient-
provided address at the time of the positive screening mammogram. Breast density was 
reported at the time of the positive screening mammogram by the interpreting radiologist 
using BI-RADS breast density classifications of almost entirely fatty, scattered 
fibrograndular densities, heterogeneously dense, and extremely dense (28, 29). At the time 
of the screening mammogram, women self-reported family history of a first-degree relative 
with breast cancer and history of a breast biopsy. The facility at the time of screening 
mammography was categorized as Hospital, Radiology private office, Comprehensive cancer 
center, Hospital outpatient center, or Primary care. Primary care included OB/GYN office, 
mobile screening units, and multispecialty clinics. Guided by results from a systematic 
review of follow-up after positive screening mammography by Zapka et al and a conceptual 
framework on cancer care delivery by Taplin et al, we identified and selected covariates for 
inclusion in both the adjusted time-to-event models and the adjusted logistic regression 
models because these covariates represent potential confounders in the relationship between 
insurance status and time to follow-up after a positive screening mammogram (30, 31). In 
addition, previous studies identified the following covariates as risk factors for delays in 
follow-up after a positive screening mammography or for breast cancer: age, race (Black 
non-Hispanic, White non-Hispanic, and Other), education, breast density, history of breast 
biopsy, family history of breast cancer, and facility type (18, 31-34).
Statistical Analysis
We described time to initial diagnostic follow-up for the study population by insurance 
status and age group at the time of the positive screening mammogram. Analyses were 
conducted separately for women younger than 65 years and for women 65 years and older at 
the time of the positive mammographic result because of the age-specific eligibility 
requirements of Medicare.
We calculated median time until initial diagnostic follow-up with interquartile range (IQR) 
and used the Kaplan-Meier estimator to construct time-to-event curves within strata of 
insurance using the first follow-up event as the endpoint (23). We confirmed the proportional 
hazards assumption by graphing the logs of the cumulative hazards. We then used the Cox 
proportional hazards regression model to estimate hazard ratios (HR) and 95% confidence 
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intervals (CI) to evaluate the association between insurance status and initial diagnostic 
follow-up after a positive screening mammogram. Women were administratively censored at 
365 days after the positive screening mammogram if a follow-up event did not occur or at 
the time that the mammography facility at which they received their positive screening 
mammogram stopped reporting data to the CMR (if applicable), whichever came first.
We also used multivariable logistic regression to estimate odds ratios and 95% confidence 
intervals for time to initial follow-up beyond 60 days based on the CDC guidelines. In both 
sets of models, the referent group for women younger than 65 years was Private insurance 
alone. The referent group in the models for ages 65 and over was Medicare & Private; 
among the older women, it was the most populous category for this age group. These models 
include women who do not receive follow-up within the study window. All p-values were 
two-sided and α <0.05 was considered statistically significant. Statistical analyses were 
performed using SAS v9.2 (SAS Institute, Cary NC). This ancillary study of CMR data was 
conducted with approval from the Institutional Review Board at The University of North 
Carolina at Chapel Hill.
Results
In the study population, approximately 81% of women included in the study self-reported 
their race as non-Hispanic White and 12% reported non-Hispanic Black (Table 1). The mean 
age for the study population was 57 years (SD=12). The majority of women under 65 years 
of age reported having private insurance (89%) followed by Medicare plus private (18%). 
Though Black women under 65 years represented 13% of the age group, they accounted for 
16% of the uninsured in that age group. The majority (60%) of women 65 years and older 
reported Medicare & private insurance followed by Medicare only (22%).
For the study cohort, the median time until initial diagnostic follow-up after a positive 
screening mammogram was 12 days (IQR 7-22 days). Women under 65 years with no 
insurance experienced a median follow-up of 16 days (IQR 8-37) compared to women with 
private insurance, who had a median of 12 days (IQR 7-21) (Table 2). Among women 65 
years and over, those with Medicare & Medicaid experienced a median follow-up of 14 days 
(IQR 8-29) while women with private insurance experienced a median of 12 days (IQR 
7-21). The Kaplan Meier survivor curves, stratified by insurance status for women under 65 
years of age (Figure 1) and those 65 and over (Figure 2), show differences by insurance 
status in initial follow-up time were observed for the 365-day study period (p<.01).
In the time-to-event analysis, approximately 10% of women had no follow-up in the study 
period (365 days) after their positive screening mammogram (Table 2). While the 
proportions of women who did and who did not receive follow-up during the study period 
differed statistically by race, age, education level, and breast density (p-value<0.0001), the 
differences in proportions were small (Supplemental Table S1). Among women who 
received no follow-up during the study period, there were slight differences in ever receiving 
follow-up by age group. Women 65 years and over were more likely to receive follow-up 
within the study period of 365 days than women under 65 years (8% versus 11% with no 
follow-up within 365 days, respectively).
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In the adjusted time-to-event model for women under 65 years, when compared to women 
with private insurance, uninsured women experienced a longer time to initial diagnostic 
follow-up with HR=0.47 (95% CI=0.25-0.89) (Table 3). Among women under 65 years, we 
did not observe statistically significant differences between private insurance only (the 
referent group) and the following insurance groups: Medicaid only, Medicare only, Medicare 
& Medicaid, and Medicare & private, although all but Medicare & private had HRs less than 
1.0. In the adjusted model, among women 65 years and over, when compared to those with 
Medicare plus private insurance, women with private insurance experienced a faster time to 
initiation of follow-up with HR=2.09 (95% CI=1.27-3.44). Among women 65 years and 
over we did not observe statistically significant differences between Medicare & private 
insurance (the referent group) and the following insurance groups: Medicare and Medicare 
& Medicaid. In the model including all other covariates, among women 65 years and older 
with an assessment of BI-RADS 5 experienced a faster time to initial diagnostic follow-up 
when compared to women with an assessment of BI-RADS 0 in the same age category (HR 
1.62, 95% CI 1.09-2.42). We did not observe statistically significant differences for BI-
RADS assessment among women under 65 years of age.
In the logistic regression analysis, about 12% of all women in the study did not receive 
initial diagnostic follow-up within 60 days of their positive screening mammogram as 
recommended by CDC guidelines. This 12% includes women who received follow-up 
beyond 60 days and those who do not receive follow-up within 365 days (Table 2). Among 
women under 65 years, nearly 18% of women without insurance received initial diagnostic 
follow-up after 60 days compared to 11% of women with private insurance. Women 65 years 
and over were slightly more likely than younger women to have follow-up greater than 60 
days (13%). Among women 65 years and over, women reporting Medicare & Medicaid were 
slightly more likely to receive initial follow-up after 60 days.
In the adjusted logistic regression model for women under 65 years, when compared to 
women with private insurance, uninsured women had increased odds of delay (OR 1.59, 
95% CI 1.31-1.94) (Table 4). No other insurance groups in this age among women <65 years 
indicated significant odds of delay. Among women 65 years and over, we did not observe 
statistically significant differences between Medicare & private insurance (the referent 
group) and the other insurance groups in adjusted models. We did not find modification of 
the insurance-delay relationship by educational status for either age group.
Discussion
We examined insurance as a predictor of time to initial diagnostic follow-up in a large 
population-based mammography registry and found that among women less than 65 years of 
age, women without insurance experienced a longer time to initial diagnostic follow-up 
compared to women with private insurance. It is important to note that the difference in days 
to initiation between the insurance groups is small and may not represent a clinically 
significant difference. Among women ages 65 and older, women with private only insurance 
experienced a faster time to initial diagnostic follow-up compared with women with 
Medicare and private insurance. These women may be more economically advantaged with 
increased access to care. In the multivariable logistic regression models, uninsured women 
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less than 65 years of age were 1.59 times more likely to experience a delay when compared 
to the privately insured in the same age group. There were no observed statistically 
significant associations between insurance status and delay among women 65 years of age 
and over.
Few population-based studies have examined the impact of insurance status and time until 
initial diagnostic follow-up after a positive screening mammogram. A study of time between 
initial consult and diagnosis reports hazard ratio estimates of four levels of insurance and the 
uninsured, but includes women with symptoms (35). Other studies focused on homogenous 
populations including, for example, only Medicaid beneficiaries (18, 36, 37). In many 
studies of breast cancer outcomes, Medicaid enrollment is a predictor of poor health 
outcomes. (20, 35, 38, 39) In this study, we did not find that Medicaid insurance was 
associated with a longer time to initial diagnostic follow-up after a positive screening 
mammogram, regardless of age group.
Other studies combined insurance groups, specifically Medicare and Medicaid to create a 
public or government category and compared this to all others included in the study (33, 
40-43). Similarly, other studies grouped Medicaid and those without insurance (44), which 
may mask benefits in time to follow-up experienced by those with Medicaid. This may lead 
to less informative conclusions because eligibility requirements for government-sponsored 
insurance programs such as Medicare and Medicaid are largely based on specific guidelines 
for age, income status, and disability status (45, 46). Additionally, the insurance categories 
may represent populations with varying barriers for seeking care such as disability or 
comorbidities. An urban hospital-based study found that women with private insurance 
reached resolution of their positive mammogram faster than those with government 
insurance, a combination of people with Medicare and Medicaid (47). A recent study of 
women enrolled in a patient navigation program assessing the impact of barriers to care after 
a positive screen, one of which was insurance, reported that women with an insurance 
barrier experienced a longer time to diagnostic follow-up after a positive screening 
mammogram (HR=0.85, 95% CI=0.74-0.97) (48). Another study comparing those with no 
insurance to those with only hospitalization insurance found that insurance was not 
associated with completing diagnostic follow-up (49). While these studies provided helpful 
information regarding a broad effect of insurance on resolution of a positive mammogram, 
they do not provide information on how resolution of a positive screening mammogram may 
vary by specific categories of insurance.
Median follow-up times to initial diagnostic follow-up in the current study were similar to 
prior studies (40, 50, 51). Specifically, a study of women attending an urban academic 
medical center in a federally designated medically underserved area reported a median 
follow-up time (defined as days between the positive mammogram and additional imaging) 
of 14 days (40). However, this study did not investigate differences by insurance status. 
Other studies report median time to complete follow-up between 20 and 50 days (32, 33, 49, 
52).
In the current time-to-event analysis, 10% of women had no initial diagnostic follow-up 
within 365 days of their positive screening mammogram. It is challenging to compare our 
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results regarding no follow-up with other studies as many studies fail to describe women 
with no follow-up after a positive screening mammogram (32, 53, 54) or exclude these 
women from the analysis (55). It may be the case that women who never receive follow-up 
are different than those who are delayed but do eventually receive follow-up.
In the current study, nearly 12% of women did not receive initial diagnostic follow-up within 
60 days after a positive screening mammogram. A study of CDC's National Breast and 
Cervical Cancer Early Detection screening program found that 20% of women did not 
receive any diagnostic follow-up within 60 days of a positive screening mammogram (37). 
Other studies of complete diagnostic follow-up after a positive screening mammogram 
report similar results: 20-40% of women receive diagnostic follow-up more than 60 days 
after a positive screening mammogram or fail to receive diagnostic follow-up entirely (36, 
37, 52, 56, 57). These estimates are slightly higher than those reported in our study and may 
be explained by differences in study populations, since these studies were conducted in 
hospitals or academic medical centers and our population represents women screened in 
community practices. Though there are no national or population-based estimates for the 
proportion of positive screening mammograms that do not receive diagnostic follow-up with 
which to compare, our study falls within the reported range (9-50%) from other studies (30, 
31, 57, 58).
It is uncertain if the differences of a few days, as illustrated by the median differences, in 
initial follow-up after a positive screening mammogram by insurance status represent 
variation of clinical significance. Medians may mask extreme differences in follow-up. We 
also provide results in terms of the dichotomous outcome of having received follow-up 
within 60 days, as recommended by the CDC. By presenting estimates from both sets of 
models by insurance type, we give more information about differences in delay. Recognizing 
potential delays experienced at follow-up and diagnosis may be important when considering 
the breast cancer care continuum and potential delays experienced at other points of care 
coordination such as treatment. As previously shown, delays in diagnosis may be indicative 
of delays in treatment (34).
The strengths of our study include the use of prospectively collected data, a diverse 
population, and large sample size. Moreover, the CMR data are longitudinal providing the 
opportunity to follow individual women receiving screening mammograms and subsequent 
breast imaging and biopsy. Prior studies were often limited by small sample sizes or focused 
on one insurance status and did not allow for examination by more insurance categories 
while also including the uninsured. In addition, previous studies frequently relied on 
administrative databases designed for billing purposes rather than research, and thus lack 
crucial information on the mammogram result. Exclusive use of patient questionnaires or 
medical records may lack complete dates of services to ensure sufficient documentation of 
time until diagnostic follow-up. In contrast, the CMR data contain detailed information on 
breast imaging procedures performed including the date of procedure as well as the 
radiologists’ interpretation of the mammogram.
Our study also has several limitations. Insurance status from the CMR is self-reported and 
may not be completely accurate. We are unable to confirm the payer for each imaging and 
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biopsy received during the study period. However, other studies found that self-report of 
insurance payer can be fairly accurate for both mammography (59) and non-mammography 
settings (60, 61) It is also possible that some follow-up visits were not captured in the CMR 
if a woman received her diagnostic follow-up care outside of the CMR catchment area. 
There may be bias due to unmeasured confounding. Some factors that may influence 
healthcare outcomes are not collected by CMR such as income, co-morbidities, access to 
transportation, social support, etc. It is possible that these factors may impact the patient's 
screening behaviors such as the ability to undergo diagnostic procedures or the frequency 
with which they interact with the healthcare system and could explain the differences in 
follow-up observed in this study (62). Furthermore, patient-reported outcomes after a 
positive screening mammogram such as anxiety, fear, stress, satisfaction with care received 
at the time of the screening mammogram, and quality of life have been shown to impact 
delays in follow-up and while beyond the scope of our analyses, should be considered in 
future work (16, 38, 43, 48, 58). Finally, we were unable to assess the potential interaction 
between insurance status and known factors associated with diagnostic delay (such as race 
and education) due to small numbers but this remains another important area of future work.
In summary, to maximize the benefits of screening mammography it is important that 
women receive appropriate and timely follow-up after a positive screening mammogram, 
especially if the follow-up delays necessary treatment. Additionally, it is important to 
understand how insurance impacts follow-up after a positive screening mammogram. We 
found differences in time to initial diagnostic follow-up after a positive screening 
mammogram by insurance status as well as by age group. Our findings that 8-14% of 
women with a positive screening mammogram do not receive follow-up within 365 days is 
concerning since this may have a significant clinical impact on time to diagnosis and receipt 
of treatment. Future research on the variation in the proportion of women with no follow-up 
at 365 days by insurance status should be undertaken to further understand how to target 
groups experiencing longer time to follow-up.
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Figure 1. 
Comparison of the Kaplan-Meier estimates of the time-to-event curve stratified by insurance 
status for women less than 65 years old receiving a positive screening mammogram between 
1995-2010. Tick marks represent observations in time as each woman experiences the 
follow-up event.
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Figure 2. 
Comparison of the Kaplan-Meier estimates of the time-to-event curve stratified by insurance 
status for women 65 years and older receiving a positive screening mammogram between 
1995-2010. Tick marks represent observations in time as each woman experiences the 
follow-up event.
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Table 2
Median and mean time to initial diagnostic follow-up in days, proportion with follow-up greater than 60 days, 
and proportion with no follow-up for women ages 40 years and older receiving a positive screening 
mammogram between 1995-2010 by insurance status, stratified at 65 years of age
Insurance Status Median (IQR)a Mean (SD) % with follow-up > 60 days % with no follow-up within 365 days
All 12 (7-22) 43 (116) 11.9 10.1
Age <65 years
No Insurance 16 (8-37) 62 (166) 17.5 13.8
Medicaid Only 14 (7-27) 47 (121) 12.9 8.5
Medicare Only 15 (8-28) 53 (159) 15.5 9.6
Medicare & Medicaid 14 (8-29) 60 (220) 14.0 9.5
Medicare & Private 13 (7-24) 42 (80) 13.0 8.2
Private Only 12 (7-21) 40 (108) 11.0 10.9
All, <65 12 (7-22) 41 (114) 11.4 10.8
Age 65+ years
Medicare Only 13 (7-26) 54 (135) 14.5 8.8
Medicare & Medicaid 14 (8-29) 55 (142) 15.9 8.8
Medicare & Private 12 (7-21) 44 (118) 12.5 7.7
Private Only 12 (7-21) 40 (87) 11.5 10.6
All, 65+ 13 (7-22) 46 (121) 13.2 8.3
a
Interquartile range (IQR) reported as a range; from the 25th percentile to the 75th percentile.
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Table 3
Unadjusted and adjusted hazard ratio (HR) estimates and 95% confidence intervals (CI) of the association 
between insurance status and time to initial diagnostic follow-up after a positive screening mammogram for 
women younger than 65 years and women 65 years and older between 1995-2010
Unadjusted Adjustedb
Insurance Status Hazard Ratio 95% CI p-valuea Hazard Ratio 95% CI p-valuea
Age <65 Years
No Insurance 0.59 0.33-1.06 0.08 0.47 0.25-0.89 0.02
Medicaid Only 0.75 0.44-1.28 0.28 0.81 0.46-1.42 0.46
Medicare Only 0.86 0.44-1.67 0.65 0.95 0.47-1.91 0.88
Medicare & Medicaid 0.63 0.32-1.24 0.18 0.50 0.24-1.02 0.06
Medicare & private 2.16 1.07-4.38 0.03 1.81 0.86-3.83 0.12
Private Only (Referent) 1.00 . . 1.00 . .
Age 65+ Years
Medicare Only 0.89 0.66-1.20 0.44 0.97 0.70-1.34 0.83
Medicare & Medicaid 0.79 0.49-1.27 0.33 0.99 0.57-1.74 0.99
Medicare & private (Referent) 1.00 . . 1.00 . .
Private Only 1.92 1.22-3.03 0.005 2.09 1.27-3.44 <0.01
aAll p-values are two-sided and α<0.05 was considered statistically significant.
b
The adjusted model includes race, education, breast density, categorical age, history of breast biopsy, family history of breast cancer, and facility 
type.
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Table 4
Unadjusted and adjusted odds ratio (OR) estimates and 95% confidence intervals (CI) of the association 
between insurance status and time to initial diagnostic follow-up of more than 60 days after a positive 
screening mammogram for women younger than 65 years and women 65 years and older between 1995-2010
Unadjusted Adjustedb
Insurance Status Odds Ratio 95% CI p-valuea Hazard Ratio 95% CI p-valuea
Age <65 Years
No Insurance 1.61 1.38-1.89 <0.0001 1.59 1.31-1.94 <0.0001
Medicaid Only 0.97 0.82-1.14 0.70 1.00 0.82-1.21 0.9603
Medicare Only 1.19 0.98-1.43 0.08 1.21 0.97-1.52 0.09
Medicare & Medicaid 1.09 0.88-1.36 0.43 1.09 0.85-1.42 0.49
Medicare & private 0.95 0.77-1.17 0.62 1.10 0.87-1.40 0.43
Private Only (Referent) 1.00 . . 1.00 . .
Age 65+ Years
Medicare Only 1.21 1.08-1.35 0.001 1.14 0.99-1.30 0.06
Medicare & Medicaid 1.29 1.08-1.56 0.006 0.96 0.76-1.20 0.73
Medicare & private (Referent) 1.00 . . 1.00 . .
Private Only 1.12 0.96-1.31 0.16 1.14 0.95-1.36 0.16
aAll p-values are two-sided and α<0.05 was considered statistically significant
b
The adjusted model includes race, education, breast density, categorical age, history of breast biopsy, family history of breast cancer, and facility 
type
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